Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-056479

Flexion Therapeutics Inc · FLXN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Neil Bodick
Officer — Chief Scientific Officer
Period of report
Oct 6, 2017
Accepted (ET)
Oct 10, 2017 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Oct 6, 2017M4,566—A64,503D
Common StockOct 6, 2017F1,598$29.9346D62,905D
Common StockF2holding———388,683IBy Versant Development Fund III, LLC

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock Unit AwardF1,F3—Oct 6, 2017M4,566D—Oct 6, 2019Common Stock4,5669,134D

Explanation of responses